{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Nkarta, Inc."},"Symbol":{"label":"Symbol","value":"NKTX"},"Address":{"label":"Address","value":"6000 SHORELINE COURT,SUITE 102, SOUTH SAN FRANCISCO, California, 94080, United States"},"Phone":{"label":"Phone","value":"+1 415 582-4923"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Nkarta Inc is a biopharmaceutical company developing engineered natural killer (NK) cells to fight cancer. The company is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. It is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. The company's operations are based in South San Francisco, California and it operates in one segment."},"CompanyUrl":{"label":"Company Url","value":"https://www.nkartatx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"David R. Shook","title":"Chief Medical Officer, Head-Research & Development"},{"name":"Paul J. Hastings","title":"Chief Executive Officer & Director"},{"name":"Ralph Brandenberger","title":"Chief Technical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}